Amal Therapeutics

Company created in 2012

Development of a new generation of therapeutic vaccines against cancer, with glioma as the initial target.

Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Genève
Switzerland